# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.88) per share. This is a 163.47 percent decrease over lo...
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-...
Calliditas Therapeutics AB (NASDAQ:CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open...
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefeco...
Calliditas Therapeutics AB (NASDAQ:CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has ...